| Authors: |
Fontana M; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, United Kingdom., Ambardekar AV; Department of Medicine, Division of Cardiology, University of Colorado, Aurora, CO, USA., Cappelli F; Tuscan Regional Amyloidosis Center, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy., Cuddy SAM; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA., Davis MK; Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada., Garcia-Pavia P; Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHIM, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain., Hanna M; Amyloidosis Center, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA., Khouri MG; Department of Medicine, Division of Cardiology, Duke University Hospital System, Durham, NC, USA., Masri A; Division of Cardiovascular Medicine, Oregon Health and Sciences University, Portland, OR, USA., Maurer MS; Columbia University Irving Medical Center, New York, NY, USA., Obici L; Amyloidosis Research and Treatment Centre, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy., Solomon S; Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA., Sperry BW; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Tahara N; Division of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume, Japan., Waddington-Cruz M; Centro de Paramiloidose Antônio Rodrigues de Mello (CEPARM), Amyloidosis Center, University Hospital, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; Amyloidosis Center, Complexo Hospitalar Américas- Samaritano-Vitória, Barra da Tijuca, Rio de Janeiro, Brazil., Conrad T; Statistics, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Rockville, MD, USA., Yang Q; Ionis Pharmaceuticals, Carlsbad, CA, USA., Chen J; Late-Stage Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MA, USA., Tsimikas S; Ionis Pharmaceuticals, Carlsbad, CA, USA., Gillmore JD; National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, United Kingdom. |
